Informed consent and follow up in aTTom trial are inadequate

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7055.494 (Published 24 August 1996) Cite this as: BMJ 1996;313:494
  1. Hazel Cunnigham, Former assistant specialist
  1. University of Hawaii School of Public Health 166 L Waiahu Beach Road, Wailuku, HI 95793, USA

    EDITOR,—The fact that women will be given adjuvant tamoxifen for more than five years despite the National Cancer Institute's warning that longer term treatment may do more harm than good is not the only reason why doctors and the public should reject the controversial aTTom (adjuvant tamoxifen treatment—offer more?) trial in breast cancer and its international counterpart, ATLAS (adjuvant tamoxifen—longer against shorter).1 2

    The megatrial was designed to “impose no extra workload on collaborators, other than randomizing and treating their …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription